{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:58:09Z","timestamp":1792799889793,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s11882-020-0895-x","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T11:04:48Z","timestamp":1578395088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Role of Eosinophils in Immunotherapy"],"prefix":"10.1007","volume":"20","author":[{"given":"Joseph","family":"Cafone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2943-9944","authenticated-orcid":false,"given":"Melanie A.","family":"Ruffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4658-5353","authenticated-orcid":false,"given":"Jonathan M.","family":"Spergel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,7]]},"reference":[{"key":"895_CR1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJM199010113231505","volume":"323","author":"J Bousquet","year":"1990","unstructured":"Bousquet J, Chanez P, Lacoste JY, Barn\u00e9on G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323:1033\u20139.","journal-title":"N Engl J Med"},{"key":"895_CR2","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","volume":"3","author":"DB Price","year":"2015","unstructured":"Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3:849\u201358.","journal-title":"Lancet Respir Med"},{"key":"895_CR3","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ajh.24880","volume":"92","author":"J Gotlib","year":"2017","unstructured":"\u2022\u2022 Gotlib J. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92:1243\u201359 WHO classification of Eosinophilia.","journal-title":"Am J Hematol"},{"key":"895_CR4","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood."},{"key":"895_CR5","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jaip.2015.06.009","volume":"3","author":"JJ Jin","year":"2015","unstructured":"Jin JJ, Butterfield JH, Weiler CR. Hematologic malignancies identified in patients with hypereosinophilia and hypereosinophilic syndromes. J Allergy Clin Immunol Pract. 2015;3:920\u20135.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"895_CR6","doi-asserted-by":"crossref","first-page":"9095275","DOI":"10.1155\/2018\/9095275","volume":"2018","author":"GA Ramirez","year":"2018","unstructured":"Ramirez GA, Yacoub M-R, Ripa M, Mannina D, Cariddi A, Saporiti N, et al. Eosinophils from physiology to disease: a comprehensive review. Biomed Res Int. 2018;2018:9095275.","journal-title":"Biomed Res Int"},{"key":"895_CR7","first-page":"111","volume":"4","author":"V Havelange","year":"2013","unstructured":"Havelange V, Demoulin J-B. Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia. J Blood Med. 2013;4:111\u201321.","journal-title":"J Blood Med"},{"key":"895_CR8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.iac.2015.04.004","volume":"35","author":"L Falchi","year":"2015","unstructured":"Falchi L, Verstovsek S. Eosinophilia in hematologic disorders. Immunol Allergy Clin N Am. 2015;35:439\u201352.","journal-title":"Immunol Allergy Clin N Am"},{"key":"895_CR9","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/0091-6749(94)90347-6","volume":"94","author":"KM Leiferman","year":"1994","unstructured":"Leiferman KM. Eosinophils in atopic dermatitis. J Allergy Clin Immunol. 1994;94:1310\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"895_CR10","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/pai.12607","volume":"27","author":"S Rossberg","year":"2016","unstructured":"Rossberg S, Gerhold K, Geske T, Zimmermann K, Menke G, Zaino M, et al. Elevated blood eosinophils in early infancy are predictive of atopic dermatitis in children with risk for atopy. Pediatr Allergy Immunol. 2016;27:702\u20138.","journal-title":"Pediatr Allergy Immunol"},{"key":"895_CR11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/ACI.0b013e32834c3134","volume":"11","author":"DJ Fitzhugh","year":"2011","unstructured":"Fitzhugh DJ, Lockey RF. Allergen immunotherapy: a history of the first 100 years. Curr Opin Allergy Clin Immunol. 2011;11:554\u20139.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"895_CR12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archotol.133.7.701","volume":"133","author":"SA Poznanovic","year":"2007","unstructured":"Poznanovic SA, Kingdom TT. Total IgE levels and peripheral eosinophilia: correlation with mucosal disease based on computed tomographic imaging of the paranasal sinus. Arch Otolaryngol Head Neck Surg. 2007;133:701\u20134.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"895_CR13","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1067\/mai.2001.119411","volume":"108","author":"PG Woodruff","year":"2001","unstructured":"Woodruff PG, Khashayar R, Lazarus SC, Janson S, Avila P, Boushey HA, et al. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol. 2001;108:753\u20138.","journal-title":"J Allergy Clin Immunol"},{"key":"895_CR14","doi-asserted-by":"crossref","first-page":"545\u2013554.e4","DOI":"10.1016\/j.jaip.2017.05.032","volume":"6","author":"WG Teague","year":"2018","unstructured":"Teague WG, Phillips BR, Fahy JV, Wenzel SE, Fitzpatrick AM, Moore WC, et al. Baseline features of the Severe Asthma Research Program (SARP III) cohort: differences with age. J Allergy Clin Immunol Pract. 2018;6:545\u2013554.e4.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"895_CR15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fmed.2017.00139","volume":"4","author":"E Doran","year":"2017","unstructured":"Doran E, Cai F, Holweg CTJ, Wong K, Brumm J, Arron JR. Interleukin-13 in asthma and other eosinophilic disorders. Front Med (Lausanne). 2017;4:139.","journal-title":"Front Med (Lausanne)"},{"key":"895_CR16","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1056\/NEJMra1502863","volume":"373","author":"GT Furuta","year":"2015","unstructured":"Furuta GT, Katzka DA. Eosinophilic esophagitis. N Engl J Med. 2015;373:1640\u20138.","journal-title":"N Engl J Med"},{"key":"895_CR17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.anai.2018.05.035","volume":"121","author":"JM Spergel","year":"2018","unstructured":"Spergel JM, Dellon ES, Liacouras CA, Molina-Infante J, Furuta GT, Spergel JM, et al. Summary of the updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Ann Allergy Asthma Immunol. 2018;121:281\u20134.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"895_CR18","first-page":"418\u2013426.e4","volume":"7","author":"RL Wasserman","year":"2019","unstructured":"Wasserman RL, Hague AR, Pence DM, Sugerman RW, Silvers SK, Rolen JG, et al. Real-world experience with peanut oral immunotherapy: lessons learned from 270 patients. J Allergy Clin Immunol Pract. 2019;7:418\u2013426.e4.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"895_CR19","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jaip.2017.02.004","volume":"5","author":"JP Abonia","year":"2017","unstructured":"Abonia JP, Spergel JM, Cianferoni A. Eosinophilic esophagitis: a primary disease of the esophageal mucosa. J Allergy Clin Immunol Pract. 2017;5:951\u20135.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"895_CR20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.anai.2018.06.013","volume":"121","author":"M Egan","year":"2018","unstructured":"Egan M, Furuta GT. Eosinophilic gastrointestinal diseases beyond eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2018;121:162\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"895_CR21","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jaci.2014.07.026","volume":"134","author":"JM Caldwell","year":"2014","unstructured":"Caldwell JM, Collins MH, Stucke EM, Putnam PE, Franciosi JP, Kushner JP, et al. Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome. J Allergy Clin Immunol. 2014;134:1114\u201324.","journal-title":"J Allergy Clin Immunol"},{"key":"895_CR22","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jaci.2016.01.001","volume":"137","author":"RA Wood","year":"2016","unstructured":"Wood RA. Food allergen immunotherapy: current status and prospects for the future. J Allergy Clin Immunol. 2016;137:973\u201382.","journal-title":"J Allergy Clin Immunol"},{"key":"895_CR23","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1586\/17474124.2015.1065177","volume":"9","author":"AJ Burbank","year":"2015","unstructured":"Burbank AJ, Burks W. Food specific oral immunotherapy: a potential treatment for food allergy. Expert Rev Gastroenterol Hepatol. 2015;9:1147\u201359.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"895_CR24","doi-asserted-by":"crossref","first-page":"286\u201391, 291.e1\u2013","DOI":"10.1016\/j.jaci.2009.03.045","volume":"124","author":"AM Hofmann","year":"2009","unstructured":"Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH, et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol. 2009;124:286\u201391, 291.e1\u20136.","journal-title":"J Allergy Clin Immunol"},{"key":"895_CR25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0091-6749(91)90297-2","volume":"88","author":"MJ Furin","year":"1991","unstructured":"Furin MJ, Norman PS, Creticos PS, Proud D, Kagey-Sobotka A, Lichtenstein LM, et al. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol. 1991;88:27\u201332.","journal-title":"J Allergy Clin Immunol"},{"key":"895_CR26","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1046\/j.1365-2222.2001.01231.x","volume":"31","author":"DR Wilson","year":"2001","unstructured":"Wilson DR, Irani AM, Walker SM, Jacobson MR, Mackay IS, Schwartz LB, et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy. 2001;31:1705\u201313.","journal-title":"Clin Exp Allergy"},{"key":"895_CR27","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1399-3038.2006.00443.x","volume":"17","author":"K-H Lue","year":"2006","unstructured":"Lue K-H, Lin Y-H, Sun H-L, Lu K-H, Hsieh J-C, Chou M-C. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol. 2006;17:408\u201315.","journal-title":"Pediatr Allergy Immunol"},{"key":"895_CR28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2500\/ajra.2010.24.3501","volume":"24","author":"S-T Kim","year":"2010","unstructured":"Kim S-T, Han DH, Moon IJ, Lee CH, Min Y-G, Rhee C-S. Clinical and immunologic effects of sublingual immunotherapy on patients with allergic rhinitis to house-dust mites: 1-year follow-up results. Am J Rhinol Allergy. 2010;24:271\u20135.","journal-title":"Am J Rhinol Allergy"},{"key":"895_CR29","doi-asserted-by":"crossref","first-page":"1103\u201310, 1110.e","DOI":"10.1016\/j.jaci.2009.02.012","volume":"123","author":"G Di Lorenzo","year":"2009","unstructured":"Di Lorenzo G, Mansueto P, Pacor ML, Rizzo M, Castello F, Martinelli N, et al. Evaluation of serum s-IgE\/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. J Allergy Clin Immunol. 2009;123:1103\u201310, 1110.e1\u20134.","journal-title":"J Allergy Clin Immunol"},{"key":"895_CR30","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.anai.2017.11.016","volume":"120","author":"DM Petroni","year":"2018","unstructured":"Petroni DM. Spergel JM Eosinophilic esophagitis and symptoms possibly related to eosinophilic esophagitis in oral immunotherapy. Ann Allergy Asthma Immunol. 2018;120:237\u201340.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"895_CR31","doi-asserted-by":"crossref","first-page":"1388\u20131390.e4","DOI":"10.1016\/j.jaci.2016.09.053","volume":"139","author":"MR Goldberg","year":"2017","unstructured":"Goldberg MR, Elizur A, Nachshon L, Appel MY, Levy MB, Golobov K, et al. Oral immunotherapy-induced gastrointestinal symptoms and peripheral blood eosinophil responses. J Allergy Clin Immunol. 2017;139:1388\u20131390.e4.","journal-title":"J Allergy Clin Immunol"},{"key":"895_CR32","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.4049\/jimmunol.156.11.4422","volume":"156","author":"LC Meagher","year":"1996","unstructured":"Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol. 1996;156:4422\u20138.","journal-title":"J Immunol"},{"key":"895_CR33","doi-asserted-by":"crossref","first-page":"AB403","DOI":"10.1016\/j.jaci.2017.12.950","volume":"141","author":"HS Rasmussen","year":"2018","unstructured":"\u2022\u2022 Rasmussen HS, Chang AT, Tomasevic N, Bebbington C. A randomized, double-blind, placebo-controlled, ascending dose phase 1 study of AK002, a novel Siglec-8 selective monoclonal antibody, in healthy subjects. J Allergy Clin Immunol. 2018;141:AB403 This is a Phase 1 trial which highlights the rapid depletion of eosinophils following a single dose of AK002.","journal-title":"J Allergy Clin Immunol"},{"key":"895_CR34","doi-asserted-by":"crossref","first-page":"1344\u20131353.e2","DOI":"10.1016\/j.jaci.2010.04.004","volume":"125","author":"R Kolbeck","year":"2010","unstructured":"Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125:1344\u20131353.e2.","journal-title":"J Allergy Clin Immunol"},{"key":"895_CR35","doi-asserted-by":"crossref","first-page":"4839230","DOI":"10.1155\/2018\/4839230","volume":"2018","author":"C Pelaia","year":"2018","unstructured":"Pelaia C, Calabrese C, Vatrella A, Busceti MT, Garofalo E, Lombardo N, et al. Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma. Biomed Res Int. 2018;2018:4839230.","journal-title":"Biomed Res Int"},{"key":"895_CR36","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","volume":"2","author":"M Castro","year":"2014","unstructured":"\u2022\u2022 Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al. Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2:879\u201390 This randomized, controlled, double-blind study in asthmatics highlights the potential use of peripheral eosinophil count as a biomarker in benralizumab therapy.","journal-title":"Lancet Respir Med"},{"key":"895_CR37","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/leu.2012.162","volume":"26","author":"A Pardanani","year":"2012","unstructured":"Pardanani A, D\u2019Souza A, Knudson RA, Hanson CA, Ketterling RP, Tefferi A. Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome. Leukemia. 2012;26:2439\u201341.","journal-title":"Leukemia."},{"key":"895_CR38","doi-asserted-by":"crossref","first-page":"33229","DOI":"10.18632\/oncotarget.8906","volume":"7","author":"S-Q Qu","year":"2016","unstructured":"Qu S-Q, Qin T-J, Xu Z-F, Zhang Y, Ai X-F, Li B, et al. Long-term outcomes of imatinib in patients with FIP1L1\/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China. Oncotarget. 2016;7:33229\u201336.","journal-title":"Oncotarget."},{"key":"895_CR39","first-page":"231","volume":"49","author":"CJ Sanderson","year":"1990","unstructured":"Sanderson CJ. Eosinophil differentiation factor (interleukin-5). Immunol Ser. 1990;49:231\u201356.","journal-title":"Immunol Ser"},{"key":"895_CR40","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198\u2013207.","journal-title":"N Engl J Med"},{"key":"895_CR41","doi-asserted-by":"crossref","first-page":"1742\u20131751.e7","DOI":"10.1016\/j.jaci.2018.09.033","volume":"143","author":"S Khatri","year":"2019","unstructured":"Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143:1742\u20131751.e7.","journal-title":"J Allergy Clin Immunol"},{"key":"895_CR42","doi-asserted-by":"crossref","first-page":"1024\u20131031.e14","DOI":"10.1016\/j.jaci.2017.05.044","volume":"140","author":"C Bachert","year":"2017","unstructured":"Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017;140:1024\u20131031.e14.","journal-title":"J Allergy Clin Immunol"},{"key":"895_CR43","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017;376:1921\u201332.","journal-title":"N Engl J Med"},{"key":"895_CR44","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","volume":"358","author":"ME Rothenberg","year":"2008","unstructured":"Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon H-U, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358:1215\u201328.","journal-title":"N Engl J Med"},{"key":"895_CR45","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2011.07.044","volume":"141","author":"AH Assa\u2019ad","year":"2011","unstructured":"Assa\u2019ad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology. 2011;141:1593\u2013604.","journal-title":"Gastroenterology."},{"key":"895_CR46","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","volume":"60","author":"JM Oldhoff","year":"2005","unstructured":"Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005;60:693\u20136.","journal-title":"Allergy."},{"key":"895_CR47","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","volume":"150","author":"J Corren","year":"2016","unstructured":"\u2022\u2022 Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150:799\u2013810 This Phase 3 study highlights improved outcomes in asthmatics with eosinophilia following reslizumab therapy.","journal-title":"Chest"},{"key":"895_CR48","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","volume":"129","author":"JM Spergel","year":"2012","unstructured":"Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129:456\u201363 463.e1\u20133.","journal-title":"J Allergy Clin Immunol"},{"key":"895_CR49","doi-asserted-by":"crossref","first-page":"863\u2013871.e11","DOI":"10.1016\/j.jaad.2018.01.017","volume":"78","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Ta\u00efeb A, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78:863\u2013871.e11.","journal-title":"J Am Acad Dermatol"},{"key":"895_CR50","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","volume":"3","author":"CE Brightling","year":"2015","unstructured":"Brightling CE, Chanez P, Leigh R, O\u2019Byrne PM, Korn S, She D, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3:692\u2013701.","journal-title":"Lancet Respir Med"},{"key":"895_CR51","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2014.07.049","volume":"135","author":"ME Rothenberg","year":"2015","unstructured":"Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B, Hirano I, et al. Intravenous anti\u2013IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015;135:500\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"895_CR52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","volume":"388","author":"S Wenzel","year":"2016","unstructured":"\u2022\u2022 Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31\u201344 This Phase 2 trial which reveal the potential development of transient eosinophilia following dupilumab therapy.","journal-title":"Lancet"},{"key":"895_CR53","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475\u201385.","journal-title":"N Engl J Med"},{"key":"895_CR54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","volume":"81","author":"S Faiz","year":"2019","unstructured":"Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz J-D, Reguiai Z, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81:143\u201351.","journal-title":"J Am Acad Dermatol"},{"key":"895_CR55","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389:2287\u2013303.","journal-title":"Lancet."},{"key":"895_CR56","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"\u2022\u2022 Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335\u201348 This pivotal phase 3 should the use of dupilumab in atopic dermatitis.","journal-title":"N Engl J Med"},{"key":"895_CR57","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.rmed.2009.09.011","volume":"104","author":"M Massanari","year":"2010","unstructured":"Massanari M, Holgate ST, Busse WW, Jimenez P, Kianifard F, Zeldin R. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med. 2010;104:188\u201396.","journal-title":"Respir Med"},{"key":"895_CR58","doi-asserted-by":"crossref","first-page":"485\u2013486.e11","DOI":"10.1016\/j.jaci.2013.02.032","volume":"132","author":"W Busse","year":"2013","unstructured":"Busse W, Spector S, Ros\u00e9n K, Wang Y, Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol. 2013;132:485\u2013486.e11.","journal-title":"J Allergy Clin Immunol"},{"key":"895_CR59","doi-asserted-by":"crossref","first-page":"e0113483","DOI":"10.1371\/journal.pone.0113483","volume":"10","author":"D Loizou","year":"2015","unstructured":"Loizou D, Enav B, Komlodi-Pasztor E, Hider P, Kim-Chang J, Noonan L, et al. A pilot study of omalizumab in eosinophilic esophagitis. PLoS One. 2015;10:e0113483.","journal-title":"PLoS One"},{"key":"895_CR60","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","volume":"377","author":"J Corren","year":"2017","unstructured":"Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377:936\u201346.","journal-title":"N Engl J Med"},{"key":"895_CR61","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","volume":"370","author":"GM Gauvreau","year":"2014","unstructured":"Gauvreau GM, O\u2019Byrne PM, Boulet L-P, Wang Y, Cockcroft D, Bigler J, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370:2102\u201310.","journal-title":"N Engl J Med"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-020-0895-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11882-020-0895-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-020-0895-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T20:26:00Z","timestamp":1695587160000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11882-020-0895-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["895"],"URL":"https:\/\/doi.org\/10.1007\/s11882-020-0895-x","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"7 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Spergel reports grants and personal fees from Regeneron, Sanofi, and Dbv Technologies, grants from NIH, during the conduct of the study; grants from AImmune THerapeutics, personal fees from ACAAI, outside the submitted work. The other authors have no disclosures to report during the conduct of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"1"}}